Drug Trial Radar · NCT07008378
A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis
Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
60
Planned (sponsor's estimate)
Start
Oct 15, 2025
Primary completion
Aug 31, 2032
Study completion Aug 31, 2032
Sponsor
- Lead sponsor
- Genentech, Inc.Roche (Genentech) (RHHBY)
- Sponsor type
- Industry
- Collaborators
- Poseida Therapeutics, Inc., a member of the Roche Group
- First posted
- Jun 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to explore the safety, tolerability, cellular kinetics, and pharmacodynamics of P-CD19CD20-ALLO1 in participants with progressive multiple sclerosis (PMS) and relapsing multiple sclerosis (RMS).
Conditions
- Multiple Sclerosis
Interventions
P-CD19CD20-ALLO1 CellsBiological
P-CD19CD20-ALLO1 Cells will be administered intravenously as per the schedule specified in the protocol.
CyclophosphamideDrug
Cyclophosphamide will be administered intravenously.
FludarabineDrug
Fludarabine will be administered intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose-limiting Toxicity (DLTs) at Each Dose Level of P-CD19CD20-ALLO1Time frame: Day 1 up to Day 29
- Number of Participants With Adverse Events (AEs)Time frame: Up to 5 years
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
UCSD Altman Clinical and Translational Research Institute
La Jolla, California
Washington University School of Medicine
St Louis, Missouri
Rutgers University- Robert Wood Johnson Medical School
New Brunswick, New Jersey
Multiple Sclerosis Comprehensive Care Center at Northwell Health
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.